A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN)

The recommended phase II dose for cabazitaxel in combination with cisplatin 75 mg/m2 and 5-FU 800 mg/m2/d × 4 days is 22.5 mg/m2 and for cisplatin 100 mg/m2 and 5-FU 800 mg/m2/d × 4 days is 17.5 mg/m2. With a median follow-up of 39 months, PFS for the entire non-metastatic population at 3 years was approximately 58%.